24/7 Market News Snapshot 01 July, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc. has recently seen a significant surge in its stock performance, rising 29% in pre-market trading to reach $1.690, up from the previous close of $1.310. This momentum comes with a robust trading volume of 3.83 million shares, highlighting strong investor interest and confidence in the company’s future. The spike in share value may be attributed to positive developments within the organization, suggesting that Soligenix is emerging as a noteworthy entity in the biopharmaceutical sector.
In conjunction with this market activity, Soligenix has achieved a critical milestone by successfully transferring its synthetic hypericin active ingredient manufacturing operations to the United States. This strategic move is part of the company’s collaboration with Sterling Pharma Solutions and aims to enhance the production capabilities for its novel topical treatments, HyBryte™ and SGX302, which are in development for cutaneous T-cell lymphoma (CTCL) and psoriasis.
The transition to U.S.-based manufacturing will ensure that Soligenix has access to a scalable, commercially viable production process that complies with current good manufacturing practices (cGMP). This advancement is expected to facilitate ongoing clinical trials, including the anticipated second Phase 3 study, FLASH2, which is set to commence prior to the end of 2024.
Dr. Christopher J. Schaber, President and CEO, emphasized the excitement surrounding this transition, noting the potential for larger quantities of cGMP synthetic hypericin to improve efficiency and reduce costs in production. This development aligns with Soligenix’s commitment to bringing HyBryte™ to market as a groundbreaking photodynamic therapy, further solidifying the company’s place at the forefront of treatments for rare diseases while advancing the prospects for innovative healthcare solutions.
Related news for (SNGX)
- Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
- Soligenix Announces Closing of $7.5 Million Public Offering
- Soligenix Announces Pricing of $7.5 Million Public Offering
- Breaking News: MoBot’s Latest Update as of 09/23/25 07:00 AM
- Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor